Abstract

Emergence of ICOS hi CD4 T Cells is Associated with Tumor Reduction, Progression-Free Survival, and Overall Survival in Advanced Cancer Patients Treated with Vopratelimab, an ICOS Agonist

Johan Baeck, VP, Clinical Development & Medical Affairs, Jounce Therapeutics

Vopratelimab is an ICOS agonist antibody intended to stimulate primed CD4 T effector cells. In the ICONIC trial, peripheral T cell phenotyping demonstrated emergence of an ICOS^hi subset of activated CD4 T effector cells associated with tumor reductions and improved PFS and OS, with expansion of peripheral T cell receptor clones found in the original matched archival tumor.  Future development focuses on settings in which ICOS^hi CD 4 T effector cells are primed to respond to vopratelimab.